On behalf of the Clinical Reference Group we now seek comments on a draft rimegepant (Vydura) pathway for primary care clinicians.
Please also see the separate consultation on actions of the January meeting of CRG, which includes changes to the proposed RAG status of rimegepant.
All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.
- The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to email@example.com.
- This consultation will run for six weeks and closes at 5pm on Friday 23rd February 2024.
|Draft for consultation